New advances in the molecular biology of hepatitis C virus infection: Towards the identification of new treatment targets

Gut

Volumn 61, Issue SUPPL. 1, 2012, Pages

  Ploss, Alexander ^a   Dubuisson, Jean ^b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE INHIBITOR; ALISPORIVIR; ANTIVIRUS AGENT; CASTANOSPERMINE 6 BUTYRATE; CD81 ANTIGEN; CLAUDIN 1; CYCLOSPORIN; DIACYLGLYCEROL ACYLTRANSFERASE INHIBITOR; MICRORNA 122; MIRAVIRSEN; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE; UNCLASSIFIED DRUG; UT 231B; VIRUS GLYCOPROTEIN; VIRUS RNA;

DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIFE CYCLE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MICROBIAL ACTIVITY; MIXED INFECTION; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; RNA TRANSLATION; UNSPECIFIED SIDE EFFECT; VIRAL GENETICS; VIRUS ASSEMBLY; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS PARTICLE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MOLECULAR TARGETED THERAPY; VIRUS ASSEMBLY; VIRUS REPLICATION;

EID: 84860324912     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-302048     Document Type: Review

References (158)

1. Edlin BR. Perspective: test and treat this silent killer. Nature 2011;474:S18-19.
2. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-a therapy. Science 1998;282:103-7. (Pubitemid 28471138)
3. De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005;436:953-60. (Pubitemid 41191671)
4. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-38.
5. Jacobson IM, McHutchison JG, Dusheiko G, et al ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
6. Poordad F, McCone J Jr, Bacon BR, et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
7. Kwo PY, Lawitz EJ, McCone J, et al; SPRINT-1 Investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010;376:705-16.
8. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012;366:216-24.
9. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, doseescalation trial. Lancet 2010;376:1467-75.
10. Scarselli E, Ansuini H, Cerino R, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002;21:5017-25.
11. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science 1998;282:938-41. (Pubitemid 28507525)
12. Evans MJ, von Hahn T, Tscherne DM, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007;446:801-5. (Pubitemid 46582027)
13. Liu S, Yang W, Shen L, et al. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol 2009;83:2011-14.
14. Ploss A, Evans MJ, Gaysinskaya VA, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009;457:882-6.
15. Lupberger J, Zeisel MB, Xiao F, et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011;17:589-95.
16. Rocha-Perugini V, Montpellier C, Delgrange D, et al. The CD81 partner EWI-2wint inhibits hepatitis C virus entry. PLoS One 2008;3:-1866.
17. André P, Komurian-Pradel F, Deforges S, et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002;76:6919-28. (Pubitemid 41246207)
18. Popescu CI, Dubuisson J. Role of lipid metabolism in hepatitis C virus assembly and entry. Biol Cell 2010;102:63-74.
19. Vieyres G, Thomas X, Descamps V, et al. Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol 2010;84:10159-68.
20. Pileri P, Uematsu Y, Compagnoli S, et al. Binding of hepatitis C virus to CD81. Science 1998;282:938-41. (Pubitemid 28507525)
21. Krey T, d'Alayer J, Kikuti CM, et al. The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog 2010;6:-1000762.
22. Michalak JP, Wychowski C, Choukhi A, et al. Characterization of truncated forms of hepatitis C virus glycoproteins. J Gen Virol 1997;78:2299-306. (Pubitemid 27387044)
23. Lavillette D, Pécheur EI, Donot P, et al. Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus. J Virol 2007;81:8752-65. (Pubitemid 47242848)
24. Helle F, Vieyres G, Elkrief L, et al. Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J Virol 2010;84:11905-15.
25. Andre P, Perlemuter G, Budkowska A, et al. Hepatitis C virus particles and lipoprotein metabolism. Semin Liver Dis 2005;25:93-104. (Pubitemid 40322354)
26. Bartenschlager R, Penin F, Lohmann V, et al. Assembly of infectious hepatitis C virus particles. Trends Microbiol 2011;19:95-103.
27. Andreo U, Maillard P, Kalinina O, et al. Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection. Cell Microbiol 2007;9:2445-56. (Pubitemid 47365649)
28. Merz A, Long G, Hiet MS, et al. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem 2011;286:3018-32.
29. Bartosch B, Dubuisson J. Recent advances in hepatitis C virus cell entry. Viruses 2010;2:692-709.
30. Koutsoudakis G, Kaul A, Steinmann E, et al. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol 2006;80:5308-20.
31. Sharma NR, Mateu G, Dreux M, et al. Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion. J Biol Chem 2011;286:30361-76.
32. Forns X, Thimme R, Govindarajan S, et al. Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc Natl Acad Sci U S A 2000;97:13318-23.
33. Maillard P, Huby T, Andreo U, et al. The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/Cla1 is mediated by ApoB-containing lipoproteins. FASEB J 2006;20:735-7. (Pubitemid 46671198)
34. Dorner M, Horwitz JA, Robbins JB, et al. A genetically humanized mouse model for hepatitis C virus infection. Nature 2011;474:208-11.
35. Meuleman P, Teresa Catanese M, Verhoye L, et al. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology 2011;55:364-72.
36. Dreux M, Dao Thi VL, Fresquet J, et al. Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains. PLoS Pathog 2009;5:-1000310.
37. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2001;2:285-93. (Pubitemid 33676971)
38. Zheng A, Yuan F, Li Y, et al. Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus. J Virol 2007;81:12465-71.
39. Meertens L, Bertaux C, Cukierman L, et al. The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus. J Virol 2008;82:3555-60. (Pubitemid 351429931)
40. Harris HJ, Davis C, Mullins JG, et al. Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem 2010;285:21092-102.
41. Sainz B Jr, Barretto N, Martin DN, et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 2012;18:281-5.
42. Zeisel MB, Fofana I, Fafi-Kremer S, et al. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J Hepatol 2011;54:566-76.
43. Barth H, Schafer C, Adah MI, et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 2003;278:41003-12. (Pubitemid 37280923)
44. Barth H, Schnober EK, Zhang F, et al. Viral and cellular determinants of the hepatitis C virus envelopeeheparan sulfate interaction. J Virol 2006;80:10579-90. (Pubitemid 44628904)
45. Agnello V, Abel G, Elfahal M, et al. Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 1999;96:12766-71. (Pubitemid 29513577)
46. Molina S, Castet V, Fournier-Wirth C, et al. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol 2007;46:411-19. (Pubitemid 46201721)
47. Owen DM, Huang H, Ye J, et al. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology 2009;394:99-108.
48. Albecka A, Belouzard S, de Beeck AO, et al. Role of LDL receptor in the hepatitis c virus life cycle. Hepatology. Published Online First: 26 November 2011. doi:10.1002/hep.25501
49. Catanese MT, Ansuini H, Graziani R, et al. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol 2010;84:34-43.
50. Brazzoli M, Bianchi A, Filippini S, et al. CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J Virol 2008;82:8316-29.
51. Harris HJ, Farquhar MJ, Mee CJ, et al. CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol 2008;82:5007-20. (Pubitemid 351657061)
52. Coller KE, Berger KL, Heaton NS, et al. RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. PLoS Pathog 2009;5:-1000702.
53. Blanchard E, Belouzard S, Goueslain L, et al. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol 2006;80:6964-72. (Pubitemid 44025195)
54. Mee CJ, Harris HJ, Farquhar MJ, et al. Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J Virol 2009;83:6211-21.
55. Mee CJ, Farquhar MJ, Harris HJ, et al. Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner. Gastroenterology 2010;138:1134-42.
56. Timpe JM, Stamataki Z, Jennings A, et al. Hepatitis C virus cellecell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 2008;47:17-24. (Pubitemid 351171037)
57. Witteveldt J, Evans MJ, Bitzegeio J, et al. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol 2009;90:48-58.
58. Brimacombe CL, Grove J, Meredith LW, et al. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol 2011;85:596-605.
59. Edwards VC, Tarr AW, Urbanowicz RA, et al. The role of neutralizing antibodies in hepatitis C virus infection. J Gen Virol 2012;93:1-19.
60. Meunier JC, Engle RE, Faulk K, et al. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci U S A 2005;102:4560-5. (Pubitemid 40397151)
61. Scheel TK, Gottwein JM, Jensen TB, et al. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc Natl Acad Sci U S A 2008;105:997-1002. (Pubitemid 351282070)
62. Gottwein JM, Scheel TK, Jensen TB, et al. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 2009;49:364-77.
63. Schiano TD, Charlton M, Younossi Z, et al. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl 2006;12:1381-9. (Pubitemid 44405128)
64. Meuleman P, Bukh J, Verhoye L, et al. In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. Hepatology 2011;53:755-62.
65. Helle F, Wychowski C, Vu-Dac N, et al. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J Biol Chem 2006;281:25177-83. (Pubitemid 44401904)
66. Meuleman P, Albecka A, Belouzard S, et al. Griffithsin has antiviral activity against hepatitis C virus. Antimicrob Agents Chemother 2011;55:5159-67.
67. Bertaux C, Daelemans D, Meertens L, et al. Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. Virology 2007;366:40-50. (Pubitemid 47314396)
68. Ciesek S, von Hahn T, Colpitts CC, et al. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology 2011;54:1947-55.
69. Calland N, Albecka A, Belouzard S, et al. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology2012;55:720-9
70. Baldick CJ, Wichroski MJ, Pendri A, et al. A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog 2010;6: -1001086.
71. Matsumura T, Hu Z, Kato T, et al. Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology 2009;137:673-81.
72. Liu R, Tewari M, Kong R, et al. A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. Antiviral Res 2010;86:172-9.
73. Montero A, Gastaminza P, Law M, et al. Self-assembling peptide nanotubes with antiviral activity against hepatitis C virus. Chem Biol 2011;18:1453-62.
74. Cheng G, Montero A, Gastaminza P, et al. A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 2008;105:3088-93. (Pubitemid 351723672)
75. Meuleman P, Hesselgesser J, Paulson M, et al. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 2008;48:1761-8.
76. Fofana I, Krieger SE, Grunert F, et al. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 2010;139:953-64, 964 -1-4.
77. Syder AJ, Lee H, Zeisel MB, et al. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol 2011;54:48-55.
78. Gastaminza P, Whitten-Bauer C, Chisari FV. Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection. Proc Natl Acad Sci U S A 2010;107:291-6.
79. Chockalingam K, Simeon RL, Rice CM, et al. A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle. Proc Natl Acad Sci U S A 2010;107:3764-9.
80. Bartenschlager R, Cosset FL, Lohmann V. Hepatitis C virus replication cycle. J Hepatol 2010;53:583-5.
81. Jopling CL, Schütz S, Sarnow P. Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe 2008;4:77-85. (Pubitemid 351944051)
82. Jopling CL, Yi M, Lancaster AM, et al. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005;309:1577-81. (Pubitemid 41266486)
83. Machlin ES, Sarnow P, Sagan SM. Masking the 5′ terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex. Proc Natl Acad Sci U S A 2011;108:3193-8.
84. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010;327:198-201.
85. Santolini E, Migliaccio G, La Monica N. Biosynthesis and biochemical properties of the hepatitis C virus core protein. J Virol 1994;68:3631-41. (Pubitemid 24177387)
86. McLauchlan J, Lemberg MK, Hope G, et al. Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets. EMBO J 2002;21:3980-8. (Pubitemid 34857431)
87. Pene V, Hernandez C, Vauloup-Fellous C, et al. Sequential processing of hepatitis C virus core protein by host cell signal peptidase and signal peptide peptidase: a reassessment. J Viral Hepat 2009;16:705-15.
88. Tai AW, Benita Y, Peng LF, et al. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe 2009;5:298-307.
89. Ng TI, Mo H, Pilot-Matias T, et al. Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology. Hepatology 2007;45:1413-21. (Pubitemid 46918325)
90. Supekova L, Supek F, Lee J, et al. Identification of human kinases involved in hepatitis C virus replication by small interference RNA library screening. J Biol Chem 2008;283:29-36.
91. Vaillancourt FH, Pilote L, Cartier M, et al. Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication. Virology 2009;387:5-10.
92. Randall G, Panis M, Cooper JD, et al. Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A 2007;104:12884-9. (Pubitemid 47255249)
93. Borawski J, Troke P, Puyang X, et al. Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication. J Virol 2009;83:10058-74.
94. Trotard M, Lepère-Douard C, Régeard M, et al. Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening. FASEB J 2009;23:3780-9.
95. Li Q, Brass AL, Ng A, et al. A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc Natl Acad Sci U S A 2009;106:16410-15.
96. Jones DM, Domingues P, Targett-Adams P, et al. Comparison of U2OS and Huh-7 cells for identifying host factors that affect hepatitis C virus RNA replication. J Gen Virol 2010;91:2238-48.
97. Reiss S, Rebhan I, Backes P, et al. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 2011;9:32-45.
98. Berger KL, Cooper JD, Heaton NS, et al. Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc Natl Acad Sci U S A 2009;106:7577-82.
99. Kaul A, Stauffer S, Berger C, et al. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog 2009;5: -1000546.
100. Yang F, Robotham JM, Nelson HB, et al. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J Virol 2008;82:5269-78. (Pubitemid 351705235)
101. Membreno FE, Lawitz EJ. The HCV NS5B nucleoside and non-nucleoside inhibitors. Clin Liver Dis 2011;15:611-26.
102. Lorenz IC. The hepatitis C virus nonstructural protein 2 (NS2): an up-and-coming antiviral drug target. Viruses 2010;2:1635-46.
103. Frick DN. HCV helicase: structure, function, and inhibition. In: Tan SL, eds. Hepatitis C Viruses: Genomes and Molecular Biology Chapter 7, Norfolk, Horizon Bioscience, 2006:207-44.
104. Lam AM, Frick DN. Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase. J Virol 2006;80:404-11.
105. Kolykhalov AA, Mihalik K, Feinstone SM, et al. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J Virol 2000;74:2046-51. (Pubitemid 30434065)
106. Belon CA, Frick DN. Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C. Future Virol 2009;4:277-93.
107. Paul D, Romero-Brey I, Gouttenoire J, et al. NS4B self-interaction through conserved C-terminal elements is required for the establishment of functional hepatitis C virus replication complexes. J Virol 2011;85:6963-76.
108. Elazar M, Liu P, Rice CM, et al. An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication. J Virol 2004;78:11393-400. (Pubitemid 39299681)
109. Cho NJ, Dvory-Sobol H, Lee C, et al. Identification of a class of HCV inhibitors directed against the nonstructural protein NS4B. Sci Transl Med 2010;2:15ra6.
110. Einav S, Gerber D, Bryson PD, et al. Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. Nat Biotechnol 2008;26:1019-27.
111. Einav S, Sobol HD, Gehrig E, et al. The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. J Infect Dis 2010;202:65-74.
112. Tellinghuisen TL, Foss KL, Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog 2008;4:-1000032.
113. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010;465:96-100.
114. Inoue K, Sekiyama K, Yamada M, et al. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol 2003;38:567-72. (Pubitemid 36857388)
115. Watashi K, Hijikata M, Hosaka M, et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003;38:1282-8. (Pubitemid 37314838)
116. Paeshuyse J, Kaul A, De Clercq E, et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 2006;43:761-70.
117. Li YP, Gottwein JM, Scheel TK, et al. MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5′ UTR. Proc Natl Acad Sci U S A 2011;108:4991-6.
118. Targett-Adams P, Boulant S, Douglas MW, et al. Lipid metabolism and HCV infection. Viruses 2010;2:1195-217.
119. McLauchlan J. Lipid droplets and hepatitis C virus infection. Biochim Biophys Acta 2009;1791:552-9.
120. Olofsson SO, Boström P, Andersson L, et al. Triglyceride containing lipid droplets and lipid droplet-associated proteins. Curr Opin Lipidol 2008;19:441-7.
121. Popescu CI, Rouille Y, Dubuisson J. Hepatitis C virus assembly imaging. Viruses 2011;3:2238-54.
122. Barba G, Harper F, Harada T, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A 1997;94:1200-5. (Pubitemid 27087828)
123. Moradpour D, Englert C, Wakita T, et al. Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein. Virology 1996;222:51-63. (Pubitemid 26281358)
124. Boulant S, Douglas MW, Moody L, et al. Hepatitis C virus core protein induces lipid droplet redistribution in a microtubule- and dynein-dependent manner. Traffic 2008;9:1268-82. (Pubitemid 352016286)
125. Boulant S, Targett-Adams P, McLauchlan J. Disrupting the association of hepatitis C virus core protein with lipid droplets correlates with a loss in production of infectious virus. J Gen Virol 2007;88:2204-13. (Pubitemid 47194217)
126. Miyanari Y, Atsuzawa K, Usuda N, et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007;9:1089-97. (Pubitemid 47338147)
127. Herker E, Harris C, Hernandez C, et al. Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1. Nat Med 2010;16:1295-8.
128. Rouillé Y, Helle F, Delgrange D, et al. Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. J Virol 2006;80:2832-41. (Pubitemid 43346378)
129. Masaki T, Suzuki R, Murakami K, et al. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J Virol 2008;82:7964-76.
130. Appel N, Zayas M, Miller S, et al. Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS Pathog 2008;4:-1000035.
131. Evans MJ, Rice CM, Goff SP. Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. Proc Natl Acad Sci U S A 2004;101:13038-43. (Pubitemid 39167579)
132. Lemon SM, McKeating JA, Pietschmann T, et al. Development of novel therapies for hepatitis C. Antivir Res 2010;86:79-92.
133. Jones CT, Murray CL, Eastman DK, et al. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol 2007;81:8374-83. (Pubitemid 47242811)
134. Steinmann E, Penin F, Kallis S, et al. Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog 2007;3:-103.
135. Jirasko V, Montserret R, Appel N, et al. Structural and functional characterization of nonstructural protein 2 for its role in hepatitis C virus assembly. J Biol Chem 2008;283:28546-62.
136. Jirasko V, Montserret R, Lee JY, et al. Structural and functional studies of nonstructural protein 2 of the hepatitis C virus reveal its key role as organizer of virion assembly. PLoS Pathog 2010;6: -1001233.
137. Ma Y, Anantpadma M, Timpe JM, et al. Hepatitis C virus NS2 protein serves as a scaffold for virus assembly by interacting with both structural and nonstructural proteins. J Virol 2011;85:86-97.
138. Popescu CI, Callens N, Trinel D, et al. NS2 protein of hepatitis C virus interacts with structural and non-structural proteins towards virus assembly. PLoS Pathog 2011;7:-1001278.
139. Stapleford KA, Lindenbach BD. Hepatitis C virus NS2 coordinates virus particle assembly through physical interactions with the E1-E2 glycoprotein and NS3-NS4A enzyme complexes. J Virol 2011;85:1706-17.
140. Yi M, Ma Y, Yates J, et al. Trans-complementation of an NS2 defect in a late step in hepatitis C virus (HCV) particle assembly and maturation. PLoS Pathog 2009;5:-1000403.
141. Gastaminza P, Cheng G, Wieland S, et al. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol 2008;82:2120-9. (Pubitemid 351293514)
142. Huang H, Sun F, Owen DM, et al. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A 2007;104:5848-53. (Pubitemid 47175622)
143. Mirandola S, Realdon S, Iqbal J, et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 2006;130:1661-9. (Pubitemid 43668848)
144. Mirandola S, Bowman D, Hussain MM, et al. Hepatic steatosis in hepatitis C is a storage disease due to HCV interaction with microsomal triglyceride transfer protein (MTP). Nutr Metab (Lond) 2010;7:13.
145. Chang KS, Jiang J, Cai Z, et al. Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol 2007;81:13783-93. (Pubitemid 350247871)
146. Gentzsch J, Hinkelmann B, Kaderali L, et al. Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity. Antiviral Res 2011;89:136-48.
147. Kota S, Scampavia L, Spicer T, et al. A time-resolved fluorescence-resonance energy transfer assay for identifying inhibitors of hepatitis C virus core dimerization. Assay Drug Dev Technol 2010;8:96-105.
148. Steinmann E, Pietschmann T. Hepatitis C virus p7 - a viroporin crucial for virus assembly and an emerging target for antiviral therapy. Viruses 2010;2:2078-95.
149. Qu X, Pan X, Weidner J, et al. Inhibitors of endoplasmic reticulum alpha-glucosidases potently suppress hepatitis C virus virion assembly and release. Antimicrob Agents Chemother 2011;55:1036-44.
150. Ouzounov S, Mehta A, Dwek RA, et al. The combination of interferon alpha-2b and n-butyl deoxynojirimycin has a greater than additive antiviral effect upon production of infectious bovine viral diarrhea virus (BVDV) in vitro: implications for hepatitis C virus (HCV) therapy. Antiviral Res 2002;55:425-35. (Pubitemid 35223098)
151. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007;132:1979-98. (Pubitemid 46695724)
152. Takkenberg B, de Bruijne J, Weegink C, et al. Novel therapies in hepatitis B and C. Curr Gastroenterol Rep 2008;10:81-90.
153. Yen CL, Stone SJ, Koliwad S, et al. Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. J Lipid Res 2008;49:2283-301.
154. Nahmias Y, Goldwasser J, Casali M, et al. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology 2008;47:1437-45. (Pubitemid 351702727)
155. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
156. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801.
157. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-4.
158. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9.